In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemia.
Fifty-three adult patients who presented with previously untreated acute leukemia had leukemic cells incubated in vitro with five doses of cytosine arabinoside (0.001-0.1 microgram/ml) and adriamycin (0.1-10 microgram/ml). Thymidine incorporation was measured in treated and untreated cells. Greater than 80% suppression of pretreatment thymidine incorporation after treatment with 0.004 micrograms/ml of cytosine arabinoside correlated with complete remission (CR) of the patient. A Mahalanobis' D2 score, which provides an index of the deviation of patient's in vitro drug response from the mean profile of responders, was calculated for each drug. Patients who had D2 values greater than 10 for Ara-C were less likely to respond to therapy. Patients with low D2s had rates of CR higher than predicted by the prognostic model employed at U.T.M. D. Anderson Hospital. However, unlike in our previous report, responders and non-responders were not clearly separable on the basis of the D2 value.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology / Q000627:therapeutic use*; D004247:DNA / Q000096:biosynthesis*; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors
D003561:Cytarabine; D004317:Doxorubicin; D004247:DNA; D013936:Thymidine